Breaking News Instant updates and real-time market news.

ONCY

Oncolytics

$0.43

-0.0489 (-10.14%)

07:25
10/15/19
10/15
07:25
10/15/19
07:25

Oncolytics presents clinical data highlighting pelareorep data at IOVC

Oncolytics Biotech announced that the results of a metanalysis of 13 clinical studies of the company's systemically delivered oncolytic reovirus, pelareorep, were presented during a podium presentation at the annual International Oncolytic Virus Conference, hosted at the Mayo Clinic in Rochester, MN on October 9-12, 2019. The analyses examined the effectiveness of viral replication within the tumors of patients treated systemically with pelareorep. The data demonstrated that, unlike other oncolytic viruses that require intra-tumoral delivery, intravenous systemic delivery of pelareorep resulted in 81% of patient tumor samples across multiple types of cancer testing positive for virus replication, with no infection in normal tissue. These results are from studies across a broad range of solid and liquid tumors, including metastatic disease. Key Findings from the Metanalysis: After IV delivery, 81% of patient tumor samples are positive for replicating reovirus. The average increases to 96% when melanoma and skin biopsies are excluded. Tumor types that showed a high proportion of active viral replication: breast cancer, pancreatic adenocarcinoma, multiple myeloma, colorectal cancer patients with liver metastases and high-grade glioma.

ONCY Oncolytics
$0.43

-0.0489 (-10.14%)

09/04/19
ROTH
09/04/19
INITIATION
Target $6.8
ROTH
Buy
Oncolytics initiated with a Buy at Roth Capital
Roth Capital analyst Jerry Isaacson started coverage of Oncolytics with a Buy rating and $6.80 price target given its "promising" oncolytic virus for multiple tumors. At this time, based on announced clinical plans, the analyst considers the company's lead product candidate pelareorep to have potential value in breast cancer, pancreatic cancer, and multiple myeloma, and sees potential for it to be approved in all of these indications in 2024.
09/04/19
09/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ASE Technology (ASX) initiated with a Buy at Goldman Sachs. 2. XPEL (XPEL) initiated with a Buy at Craig-Hallum. 3. Papa John's (PZZA) initiated with a Buy at Northcoast while Domino's Pizza (DPZ) was initiated with a Neutral. 4. Oncolytics (ONCY) initiated with a Buy at Roth Capital. 5. WWE (WWE) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

09:33
11/13/19
11/13
09:33
11/13/19
09:33
General news
Powell says 'noteworthy risks' to baseline economic outlook remain »

Federal Reserve Chairman…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$308.96

0.57 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$89.00

6.3 (7.62%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Recommendations
Tyson Foods analyst commentary  »

Tyson Foods price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPI

eXp World Holdings

$9.96

0.13 (1.32%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Conference/Events
eXp World Holdings management to meet with DA Davidson »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

TRPX

Therapix Biosciences

$1.41

-0.16 (-10.19%)

09:32
11/13/19
11/13
09:32
11/13/19
09:32
Hot Stocks
Therapix Biosciences says Phase IIa study of THX-110 met primary endpoint »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$255.29

-0.7 (-0.27%)

09:31
11/13/19
11/13
09:31
11/13/19
09:31
Conference/Events
House Science, Space & Technology Committee to hold a hearing »

The Subcommittee on Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

EEFT

Euronet

$149.96

1.99 (1.34%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Conference/Events
Euronet management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DG

Dollar General

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Recommendations
Dollar General analyst commentary  »

Dollar General Q3 comp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Dec

BGNE

BeiGene

$196.20

4.5 (2.35%)

09:30
11/13/19
11/13
09:30
11/13/19
09:30
Downgrade
BeiGene rating change  »

BeiGene downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 27

    Feb

DEO

Diageo

$157.94

-1.87 (-1.17%)

09:29
11/13/19
11/13
09:29
11/13/19
09:29
Conference/Events
Diageo management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

DBD

Diebold

$8.10

0.025 (0.31%)

09:28
11/13/19
11/13
09:28
11/13/19
09:28
Conference/Events
Diebold management to meet with DA Davidson »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CBPX

Continental Building

$35.76

3.73 (11.65%)

, GMS

GMS Inc.

$30.73

0.21 (0.69%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Recommendations
Continental Building, GMS Inc., Foundation Building Materials analyst commentary  »

Continental Building…

CBPX

Continental Building

$35.76

3.73 (11.65%)

GMS

GMS Inc.

$30.73

0.21 (0.69%)

FBM

Foundation Building Materials

$21.20

0.2 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CRLBF

Cresco Labs

$0.00

(0.00%)

09:27
11/13/19
11/13
09:27
11/13/19
09:27
Conference/Events
Cresco Labs management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNI

Canadian National

$93.08

-0.485 (-0.52%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
Canadian National management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 21

    Nov

  • 22

    Nov

BRTX

BioRestorative Therapies

$0.00

(0.00%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Conference/Events
BioRestorative Therapies to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TLRY

Tilray

$21.57

-0.4 (-1.82%)

09:25
11/13/19
11/13
09:25
11/13/19
09:25
Recommendations
Tilray analyst commentary  »

Tilray price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/13/19
11/13
09:25
11/13/19
09:25
General news
Fed Chair Powell goes to Capitol Hill for his JEC testimony »

Fed Chair Powell goes to…

EL

Estee Lauder

$187.89

0.63 (0.34%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 06

    Feb

BWEN

Broadwind Energy

$1.53

(0.00%)

09:24
11/13/19
11/13
09:24
11/13/19
09:24
Conference/Events
Broadwind Energy management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

BLDR

Builders FirstSource

$24.75

0.4 (1.64%)

09:22
11/13/19
11/13
09:22
11/13/19
09:22
Conference/Events
Builders FirstSource management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 05

    Dec

NVFY

Nova Lifestyle

$0.54

(0.00%)

09:21
11/13/19
11/13
09:21
11/13/19
09:21
Earnings
Nova Lifestyle reports Q3 revenue $9.3M vs. $16.7M last year »

Tawny Lam, Chairperson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMN

AMN Healthcare

$60.42

0.53 (0.88%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Conference/Events
AMN Healthcare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PHOT

GrowLife

$0.00

(0.00%)

09:20
11/13/19
11/13
09:20
11/13/19
09:20
Earnings
GrowLife reports Q3 revenue $2.3M vs. $1M last year »

GrowLife CEO Marco Hegyi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$28.32

-0.45 (-1.56%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Conference/Events
Aimmune management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NLTX

Neoleukin Therapeutics

$3.00

0.035 (1.18%)

09:19
11/13/19
11/13
09:19
11/13/19
09:19
Hot Stocks
Neoleukin Therapeutics expects cash to fund operations through 2021 »

Cash and cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLTX

Neoleukin Therapeutics

$3.00

0.035 (1.18%)

09:18
11/13/19
11/13
09:18
11/13/19
09:18
Earnings
Neoleukin Therapeutics reports Q3 EPS ($2.26), one est. (4c) »

"The past quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.